Who are Olanzapine and Amisulpride's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Sublingual film containing Igalmi, Risperidone long acting injectables, Seroquel and Risperidone, Seroquel (quetiapine), Seroquel IR - quetiapine fumarate, Oral Risperidone.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/olanzapine-and-amisulpride.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Olanzapine and Amisulpride — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Olanzapine and Amisulpride (Olanzapine and Amisulpride) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Atypical antipsychotic combination. Area: Psychiatry.

marketed Atypical antipsychotic combination Dopamine D2 receptor, Serotonin 5-HT2A receptor Psychiatry Small molecule Live · refreshed every 30 min

Target snapshot

Olanzapine and Amisulpride (Olanzapine and Amisulpride) — Heinrich-Heine University, Duesseldorf. This is a combination of two atypical antipsychotics that block dopamine and serotonin receptors to reduce psychotic symptoms and stabilize mood.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Olanzapine and Amisulpride TARGET	Olanzapine and Amisulpride	Heinrich-Heine University, Duesseldorf	marketed	Atypical antipsychotic combination	Dopamine D2 receptor, Serotonin 5-HT2A receptor
Sublingual film containing Igalmi	Sublingual film containing Igalmi	BioXcel Therapeutics Inc	marketed	Atypical antipsychotic	Dopamine D2 receptor, Serotonin 5-HT2A receptor
Risperidone long acting injectables	Risperidone long acting injectables	Janssen Korea, Ltd., Korea	marketed	Atypical antipsychotic	Dopamine D2 receptor, Serotonin 5-HT2A receptor
Seroquel and Risperidone	Seroquel and Risperidone	AstraZeneca	marketed	Atypical antipsychotic	Dopamine D2 receptor, Serotonin 5-HT2A receptor
Seroquel (quetiapine)	Seroquel (quetiapine)	AstraZeneca	marketed	Atypical antipsychotic	Dopamine D2 receptor, serotonin 5-HT2A receptor
Seroquel IR - quetiapine fumarate	Seroquel IR - quetiapine fumarate	AstraZeneca	marketed	Atypical antipsychotic	Dopamine D2 receptor, Serotonin 5-HT2A receptor
Oral Risperidone	Oral Risperidone	Zogenix, Inc.	marketed	Atypical antipsychotic	Dopamine D2 receptor, Serotonin 5-HT2A receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Atypical antipsychotic combination class)

Changhua Christian Hospital · 1 drug in this class
Heinrich-Heine University, Duesseldorf · 1 drug in this class
Taichung Veterans General Hospital · 1 drug in this class
Xian-Janssen Pharmaceutical Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Olanzapine and Amisulpride — Competitive Intelligence Brief. https://druglandscape.com/ci/olanzapine-and-amisulpride. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab